Neurology News

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today reported its fourth-quarter 2025 financial results and affirmed its key clinical development milestones. “We’re off to a strong start in 2026, having recently dosed the first patient in our global Phase 2 idiopathic pulmonary f...

CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious medical conditions, today reported its fourth quarter and full year 2025 financial and operating results and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and to provide a business update. “2025 was a very productive year for the Lineage team,” s...

NEW YORK--(BUSINESS WIRE)--Kallyope is a late-stage biotechnology company focused on developing innovative migraine and metabolic disease therapies for health challenges faced by hundreds of millions of people globally. Today the Company announced that it will present results from a Phase 2b dose-ranging study of its novel therapy elismetrep in an oral presentation at the 2026 American Academy of Neurology (AAN) Annual Meeting being held April 18-22, 2026 in Chicago, IL. Elismetrep is the only...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences. Charlie Wagner, Chief Operating and Financial Officer, and Duncan McKechnie, Chief Commercial Officer, will participate in a fireside chat at the Leerink Global Healthcare Conference on Tuesday, March 10, 2026, at 10:00 a.m. ET. Susie Lisa, Senior Vice President, Investor Relations, and Miroslava Minkova, Executive Director, Investor Relation...

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the presentation of new clinical data at the American Heart Association’s International Stroke Conference (ISC) 2026 demonstrating a 44% reduction in door-in-door-out (DIDO) time — the time required to evaluate, coordinate, and transfer a patient to a comprehensive stroke center — for patients with large vessel occlusion (LVO) stroke in regional care settings. Th...

ALAMEDA, Calif--(BUSINESS WIRE)--Science Corporation, the pioneering full-stack neural engineering company focused on restoring and extending life, today announced the close of an oversubscribed $230 million Series C financing round. The round includes participation from a distinguished group of investors, including Lightspeed Venture Partners, Khosla Ventures, Y Combinator, IQT, and Quiet Capital, among others. This financing brings the company’s total capital raised to approximately $490 mill...

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, announced today that it will effect a 1-for-8 reverse split of its common stock. Commencing with the opening of trading on the Nasdaq Capital Market on March 9, 2026, the Company’s common stock will trade on a post-split basis under the same symbol ADTX. The reverse stock split was approved by the Company’s stockholders at the r...

SYDNEY & BOSTON--(BUSINESS WIRE)--Harrison.ai today announced FDA 510(k) clearance for acute infarct triage on non-contrast CT Brain....

BEDFORD, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (NASDAQ: BIIB), today announced the publication of data from studies of the investigational medicine zorevunersen in The New England Journal of Medicine (NEJM). The publication includes results from two completed Phase 1/2a and ongoing open-label extension (OLE) studies...

MINNEAPOLIS--(BUSINESS WIRE)--Children’s Minnesota is pleased to announce a $2.5 million, state-of-the-art biplane neuroangiography suite—the region’s only facility dedicated to pediatric neurointerventional procedures. This advanced imaging technology brings new treatment options for children with a variety of cerebrovascular diseases, further expanding Children’s Minnesota’s neurosurgical capabilities. “With this advanced biplane neuroangiography suite, we are raising the bar for children in...